Keywords: bb, biotech, posts, hefty, loss, first-half, swiss
BB Biotech posts hefty loss in first-half 2001
Article | 31 July 2001
The Swiss biotechnology investment group BB Biotech has reported afirst-half 2001 loss of 246.4 million Swiss francs ($142.2 million), which it said reflected " ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
